<DOC>
	<DOCNO>NCT01760811</DOCNO>
	<brief_summary>To compare Disease free survival ( DFS ) rate preoperative cetuximab treatment follow operation postoperative radiation-cisplatin-cetuximab treatment paradigm advance oral cavity cancer , , DFS rate historical control ( RTOG 9501 EORTC 22931 study treatment surgery follow radiotherapy cisplatin ) similar stage disease .</brief_summary>
	<brief_title>CETUXIMAB Given 3 Weeks Neoadjuvant Treatment Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT</brief_title>
	<detailed_description>This non-randomized , open-label , single center phase II study , determine patient advance oral tongue cancer treat induction dos cetuximab follow treatment radiation therapy concurrently cetuximab cisplatin ( indicated positive margin extra-capsular extension ) , improve PFS improve survival feasible toxicity , compare patient treat previous clinical trial ( RTOG 9501 EORTC 22931 ) standard therapy : radiotherapy 60 Gy without 6-Gy boost ( RTOG 9501 ) 66 Gy ( EORTC 22931 ) deliver conventional fractionation regimen five once-daily session per week , cisplatin dose 100 mg/m2 day 1 , 22 , 43.. Twenty five patient recruit . Cetuximab treatment start ( day 0 ) 400 mg/m2 follow two dos 250 mg/m2 ( weekly day 7 14 ) . Surgery perform day 31 follow treatment radiation therapy concurrently cetuximab ( 250 mg/m2 , weekly ) cisplatin 35 mg/m2 ( day 70-112 ; indicate positive margin lymph node extra-capsular extension ) . PET-CT biopsy perform start cetuximab , surgery chemo-cetuximab-RT determine efficacy treatment , compare diagnostic property PET-CT biopsy . The change , treatment cetuximab , protein level saliva , tumor tissue microRNA level tumor tissue study correlate PFS . The quality life assess . Data clinical trial RTOG 9501 EORTC 22931 use historical control .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathologically confirm , previously untreated , resectable squamous cell carcinoma tongue disease stage III IV ; Age ≥18 ≤80 ; Eastern Cooperative Oncology Group ( ECOG ) Performance status 01 ; willingto give write informed consent participation study Any prior head neck malignancy malignancy last 5 year BCC ; Prior head neck radiation ; Documented evidence distant metastasis ; Pregnancy lactation ; Clinically significant cardiovascular disease ; Known hypersensitivity component treatment ; Legal incapacity ; Clinically relevant neuropathy ; Any medical psychiatric illness would compromise patient 's ability tolerate treatment , interfere study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>tongue</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>locally advanced</keyword>
	<keyword>cetuximab</keyword>
</DOC>